Show simple item record

dc.contributor.authorSiddiqui, Zishan K
dc.contributor.authorChaudhary, Mihir
dc.contributor.authorRobinson, Matthew L
dc.contributor.authorMcCall, Anna B
dc.contributor.authorPeralta, Ria
dc.contributor.authorEsteve, Rogette
dc.contributor.authorCallahan, Charles W
dc.contributor.authorManabe, Yukari C
dc.contributor.authorCampbell, James D
dc.contributor.authorJohnson, J Kristie
dc.contributor.authorElhabashy, Maryam
dc.contributor.authorKantsiper, Melinda
dc.contributor.authorFicke, James R
dc.date.accessioned2021-12-09T19:54:21Z
dc.date.available2021-12-09T19:54:21Z
dc.date.issued2021-12-01
dc.identifier.urihttp://hdl.handle.net/10713/17340
dc.description.abstractRapid antigen tests are simple to perform and provide results within 15 min. We describe our implementation and assess performance of the BinaxNOW COVID-19 Antigen Test (Abbott Laboratories) in 6,099 adults at a self-referred walk-up testing site. Participants were grouped by self-reported COVID-19 exposure and symptom status. Most (89%) were asymptomatic, of whom 17% reported potential exposure. Overall test sensitivity compared with reference laboratory reverse-transcription [RT] PCR testing was 81% (95% confidence interval [CI] 75%, 86%). It was higher in symptomatic (87%; 95% CI 80%, 91%) than asymptomatic (71%; 95% CI 61%, 80%) individuals. Sensitivity was 82% (95% CI 66%, 91%) for asymptomatic individuals with potential exposure and 64% (95% CI 51%, 76%) for those with no exposure. Specificity was greater than 99% for all groups. BinaxNOW has high accuracy among symptomatic individuals and is below the FDA threshold for emergency use authorization in asymptomatic individuals. Nonetheless, rapid antigen testing quickly identifies positive among those with symptoms and/or close contact exposure and could expedite isolation and treatment. IMPORTANCE The BinaxNOW rapid antigen COVID-19 test had a sensitivity of 87% in symptomatic and 71% asymptomatic individuals when performed by health care workers in a high-throughput setting. The performance may expedite isolation decisions or referrals for time-sensitive monoclonal antibody treatment in communities where timely COVID PCR tests are unavailable.en_US
dc.description.urihttps://doi.org/10.1128/Spectrum.01008-21en_US
dc.language.isoenen_US
dc.publisherAmerican Society for Microbiologyen_US
dc.relation.ispartofMicrobiology Spectrumen_US
dc.subjectCOVID-19en_US
dc.subjectSARS-CoV-2en_US
dc.subjectfield hospitalen_US
dc.subjectpoint-of-care testingen_US
dc.subjectrapid antigen testingen_US
dc.subjectreverse transcription PCRen_US
dc.subjectsensitivity and specificityen_US
dc.titleImplementation and Accuracy of BinaxNOW Rapid Antigen COVID-19 Test in Asymptomatic and Symptomatic Populations in a High-Volume Self-Referred Testing Siteen_US
dc.typeArticleen_US
dc.identifier.doi10.1128/Spectrum.01008-21
dc.identifier.pmid34851137
dc.source.beginpagee0100821
dc.source.endpage
dc.source.countryUnited States


This item appears in the following Collection(s)

Show simple item record